Clinical Report: Kidney Injury Linked to Semaglutide Use
Overview
This systematic review summarizes reported cases of kidney injury associated with semaglutide, highlighting the occurrence of acute kidney injury, acute renal failure, and acute interstitial nephritis. The findings indicate that adverse drug reactions can occur even at standard doses and in patients with pre-existing conditions.
Background
Semaglutide, a glucagon-like peptide-1 receptor agonist, is widely used for glycemic control and weight reduction in type 2 diabetes. Despite its efficacy, there is a growing concern regarding its safety profile, particularly the risk of kidney injury. Understanding these adverse drug reactions is crucial for clinicians to ensure patient safety and effective management.
Data Highlights
Characteristic
Details
Total Cases
20
Gender Distribution
7 males, 13 females
Age Range
29 to 83 years
ADRs Diagnosed via Biopsy
12 cases
Improvement Post-Treatment
17 patients
Key Findings
20 cases of kidney injury linked to semaglutide were identified from 18 studies.
Adverse drug reactions occurred at standard doses ranging from 0.25 to 2.0 mg.
Common diagnoses included acute kidney injury, acute renal failure, and acute interstitial nephritis.
Most patients had pre-existing medical conditions and were on concomitant medications.
17 out of 20 patients showed improvement or recovery after treatment.
Clinical Implications
Clinicians should exercise caution when prescribing semaglutide, especially in patients with underlying kidney conditions or those on multiple medications. Regular monitoring of kidney function is recommended following the initiation of semaglutide therapy.
Conclusion
The association between semaglutide and kidney injury necessitates careful patient selection and monitoring. Further research is warranted to fully understand the implications of these findings.
